These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

81 related articles for article (PubMed ID: 9244847)

  • 1. Inflammation, aspirin, and the risk of cardiovascular disease.
    Cahill MR; Perry IJ
    N Engl J Med; 1997 Aug; 337(6):422-3; author reply 423-4. PubMed ID: 9244847
    [No Abstract]   [Full Text] [Related]  

  • 2. Inflammation, aspirin, and the risk of cardiovascular disease.
    Bruno JJ
    N Engl J Med; 1997 Aug; 337(6):422; author reply 423-4. PubMed ID: 9244845
    [No Abstract]   [Full Text] [Related]  

  • 3. Inflammation, aspirin, and the risk of cardiovascular disease.
    Murray WM
    N Engl J Med; 1997 Aug; 337(6):422; author reply 423-4. PubMed ID: 9244846
    [No Abstract]   [Full Text] [Related]  

  • 4. Reduced blood platelet sensitivity to aspirin in coronary artery disease: are dyslipidaemia and inflammatory states possible factors predisposing to sub-optimal platelet response to aspirin?
    Markuszewski L; Rosiak M; Golanski J; Rysz J; Spychalska M; Watala C
    Basic Clin Pharmacol Toxicol; 2006 May; 98(5):503-9. PubMed ID: 16635110
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lack of aspirin-induced decrease in thrombin formation in subjects resistant to aspirin.
    Undas A; Placzkiewicz-Jankowska E; Zieliński L; Tracz W
    Thromb Haemost; 2007 Jun; 97(6):1056-8. PubMed ID: 17549314
    [No Abstract]   [Full Text] [Related]  

  • 6. Aspirin resistance: what, why and when?
    Shantsila E; Watson T; Lip GY
    Thromb Res; 2007; 119(5):551-4. PubMed ID: 17010411
    [No Abstract]   [Full Text] [Related]  

  • 7. High-sensitivity C-reactive protein: potential adjunct for global risk assessment in the primary prevention of cardiovascular disease.
    Guijarro C
    Circulation; 2001 Nov; 104(22):E127. PubMed ID: 11723039
    [No Abstract]   [Full Text] [Related]  

  • 8. Drug insight: aspirin resistance-fact or fashion?
    Maree AO; Cox D; Fitzgerald DJ
    Nat Clin Pract Cardiovasc Med; 2007 Mar; 4(3):E1; author reply E2. PubMed ID: 17330121
    [No Abstract]   [Full Text] [Related]  

  • 9. Lack of aspirin effect: aspirin resistance or resistance to taking aspirin?
    Cotter G; Shemesh E; Zehavi M; Dinur I; Rudnick A; Milo O; Vered Z; Krakover R; Kaluski E; Kornberg A
    Am Heart J; 2004 Feb; 147(2):293-300. PubMed ID: 14760328
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Aspirin resistance: is it real? Is it clinically significant?
    Dalen JE
    Am J Med; 2007 Jan; 120(1):1-4. PubMed ID: 17208069
    [No Abstract]   [Full Text] [Related]  

  • 11. [Clarification of mechanism of acetylsalicylic acid].
    Fredholm B
    Nord Med; 1994; 109(6-7):202-3, 205. PubMed ID: 8015917
    [TBL] [Abstract][Full Text] [Related]  

  • 12. C-reactive protein is not only an inflammatory marker but also a direct cause of cardiovascular diseases.
    Li JJ; Fang CH
    Med Hypotheses; 2004; 62(4):499-506. PubMed ID: 15050096
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Aspirin and ibuprofen: potential mediators of the cardiovascular risk due to smoking?
    Mainous AG; Pearson WS
    Fam Med; 2003 Feb; 35(2):112-8. PubMed ID: 12607808
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hypersensitivity of platelets to adenosine diphosphate in patients with stable cardiovascular disease predicts major adverse events despite antiplatelet therapy.
    Christie DJ; Kottke-Marchant K; Gorman RT
    Platelets; 2008 Mar; 19(2):104-10. PubMed ID: 17852773
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Aspirin resistance: biological and clinical implications.
    Tseeng S; Arora R
    J Cardiovasc Pharmacol Ther; 2008 Mar; 13(1):5-12. PubMed ID: 18287586
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Platelet response to low-dose enteric-coated aspirin in patients with stable cardiovascular disease.
    Maree AO; Curtin RJ; Dooley M; Conroy RM; Crean P; Cox D; Fitzgerald DJ
    J Am Coll Cardiol; 2005 Oct; 46(7):1258-63. PubMed ID: 16198840
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Is the antiplatelet effect of aspirin affected by systemic inflammation?
    Poulsen TS; Mickley H
    Ann Hematol; 2004 Nov; 83(11):728. PubMed ID: 15338199
    [No Abstract]   [Full Text] [Related]  

  • 18. Overcoming aspirin resistance: increased platelet inhibition with combination aspirin and clopidogrel and high dose aspirin therapy in aspirin resistant patients with peripheral vascular disease.
    Wong S; Morel-Kopp MC; Chen Q; Appleberg M; Ward CM; Lewis DR
    Thromb Haemost; 2006 Jun; 95(6):1042-3. PubMed ID: 16732389
    [No Abstract]   [Full Text] [Related]  

  • 19. Drug insight: aspirin resistance--fact or fashion?
    Patrono C; Rocca B
    Nat Clin Pract Cardiovasc Med; 2007 Jan; 4(1):42-50. PubMed ID: 17180149
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Variable platelet response to aspirin and clopidogrel in atherothrombotic disease.
    Maree AO; Fitzgerald DJ
    Circulation; 2007 Apr; 115(16):2196-207. PubMed ID: 17452618
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.